|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lawrence MS, Stojanov P, Polak P, Kryukov
GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH,
Roberts SA, et al: Mutational heterogeneity in cancer and the
search for new cancer-associated genes. Nature. 499:214–218. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Park CK, Cho HJ, Choi YD, Oh IJ and Kim
YC: A phase II trial of osimertinib in the second-line treatment of
non-small cell lung cancer with the EGFR T790M mutation, detected
from circulating tumor DNA: LiquidLung-O-Cohort 2. Cancer Res
Treat. 51:777–787. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen S, Ren Y and Duan P: Biomimetic
nanoparticle loading obatoclax mesylate for the treatment of
non-small-cell lung cancer (NSCLC) through suppressing Bcl-2
signaling. Biomed Pharmacother. 129:1103712020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou J, Hui X, Mao Y and Fan L:
Identification of novel genes associated with a poor prognosis in
pancreatic ductal adenocarcinoma via a bioinformatics analysis.
Biosci Rep. 39:BSR201906252019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bakht MK, Lovnicki JM, Tubman J, Stringer
KF, Chiaramonte J, Reynolds MR, Derecichei I, Ferraiuolo RM,
Fifield BA, Lubanska D, et al: Differential expression of glucose
transporters and hexokinases in prostate cancer with a
neuroendocrine gene signature: A mechanistic perspective for
18F-FDG imaging of PSMA-suppressed tumors. J Nucl Med.
61:904–910. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim S, Shin W, Lee YM, Mun S and Han K:
Differential expressions of L1-chimeric transcripts in normal and
matched-cancer tissues. Anal Biochem. 600:1137692020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang J, Guo X, Hamada T, Yokoyama S,
Nakamura Y, Zheng J, Kurose N, Ishigaki Y, Uramoto H, Tanimoto A
and Yamada S: Protective effects of peroxiredoxin 4 (PRDX4) on
cholestatic liver injury. Int J Mol Sci. 19:25092018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang J, Liu HL, Tao L, Lin XY, Yang YD,
Tan SW and Wu B: Let-7d inhibits colorectal cancer cell
proliferation through the CST1/p65 pathway. Int J Oncol.
53:781–790. 2018.PubMed/NCBI
|
|
11
|
Du SM: The SNHG16/miR-30a axis promotes
breast cancer cell proliferation and invasion by regulating RRM2.
Neoplasma. 67:567–575. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhuang S, Li L, Zang Y, Li G and Wang F:
RRM2 elicits the metastatic potential of breast cancer cells by
regulating cell invasion, migration and VEGF expression via the
PI3K/AKT signaling. Oncol Lett. 19:3349–3355. 2020.PubMed/NCBI
|
|
13
|
Xia P, Zhang H, Xu K, Jiang X, Gao M, Wang
G, Liu Y, Yao Y, Chen X, Ma W, et al: MYC-targeted WDR4 promotes
proliferation, metastasis, and sorafenib resistance by inducing
CCNB1 translation in hepatocellular carcinoma. Cell Death Dis.
12:6912021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang H, Zhang X, Li X, Meng WB, Bai ZT,
Rui SZ, Wang ZF, Zhou WC and Jin XD: Effect of CCNB1 silencing on
cell cycle, senescence, and apoptosis through the p53 signaling
pathway in pancreatic cancer. J Cell Physiol. 234:619–631. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Okayama H, Kohno T, Ishii Y, Shimada Y,
Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S,
et al: Identification of genes upregulated in ALK-positive and
EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res.
72:100–111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu L, Lu C, Huang Y, Zhou J, Wang X, Liu
C, Chen J and Le H: SPINK1 promotes cell growth and metastasis of
lung adenocarcinoma and acts as a novel prognostic biomarker. BMB
Rep. 51:648–653. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schabath MB, Welsh EA, Fulp WJ, Chen L,
Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, et
al: Differential association of STK11 and TP53 with KRAS
mutation-associated gene expression, proliferation and immune
surveillance in lung adenocarcinoma. Oncogene. 35:3209–3216. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rousseaux S, Debernardi A, Jacquiau B,
Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY,
Lantuejoul S, Hainaut P, et al: Ectopic activation of germline and
placental genes identifies aggressive metastasis-prone lung
cancers. Sci Transl Med. 5:186ra662013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Director's Challenge Consortium for the
Molecular Classification of Lung Adenocarcinoma, . Shedden K,
Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S,
Jurisica I, Giordano TJ, et al: Gene expression-based survival
prediction in lung adenocarcinoma: A multi-site, blinded validation
study. Nat Med. 14:822–827. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tungsukruthai S, Sritularak B and
Chanvorachote P: Cycloartobiloxanthone inhibits migration and
invasion of lung cancer cells. Anticancer Res. 37:6311–6319.
2017.PubMed/NCBI
|
|
21
|
Stoellinger HM and Alexanian AR:
Modifications to the transwell migration/invasion assay method that
eases assay performance and improves the accuracy. Assay Drug Dev
Technol. 20:75–82. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu L, Wang X, Wang W, Sun M, Choi WJ, Kim
JY, Hao C, Li S, Qu A, Lu M, et al: Enantiomer-dependent
immunological response to chiral nanoparticles. Nature.
601:366–373. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheng Y, Shen Z, Gao Y, Chen F, Xu H, Mo
Q, Chu X, Peng CL, McKenzie TT, Palacios BE, et al: Phase
transition and remodeling complex assembly are important for
SS18-SSX oncogenic activity in synovial sarcomas. Nat Commun.
13:27242022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li HJ, Ke FY, Lin CC, Lu MY, Kuo YH, Wang
YP, Liang KH, Lin SC, Chang YH, Chen HY, et al: ENO1 promotes lung
cancer metastasis via HGFR and WNT signaling-driven
epithelial-to-mesenchymal transition. Cancer Res. 81:4094–4109.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li H, Han D, Hou Y, Chen H and Chen Z:
Statistical inference methods for two crossing survival curves: A
comparison of methods. PLoS One. 10:e01167742015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim GS, Kang J, Bang SW and Hwang DS: Cdc6
localizes to S- and G2-phase centrosomes in a cell cycle-dependent
manner. Biochem Biophys Res Commun. 456:763–767. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Z, Qi F and Li F: Establishment of a
gene signature to predict prognosis for patients with lung
adenocarcinoma. Int J Mol Sci. 21:84792020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qin J, Xu Z, Deng K, Qin F, Wei J, Yuan L,
Sun Y, Zheng T and Li S: Development of a gene signature associated
with iron metabolism in lung adenocarcinoma. Bioengineered.
12:4556–4568. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Behera M, Owonikoko TK, Gal AA, Steuer CE,
Kim S, Pillai RN, Khuri FR, Ramalingam SS and Sica GL: Lung
adenocarcinoma staging using the 2011 IASLC/ATS/ERS classification:
A pooled analysis of adenocarcinoma in situ and minimally invasive
adenocarcinoma. Clin Lung Cancer. 17:e57–e64. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ye S, Liu Y, Fuller AM, Katti R, Ciotti
GE, Chor S, Alam MZ, Devalaraja S, Lorent K, Weber K, et al: TGFβ
and hippo pathways cooperate to enhance sarcomagenesis and
metastasis through the hyaluronan-mediated motility receptor
(HMMR). Mol Cancer Res. 18:560–573. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang D, Ma Y, Zhao P, Ma J and He C:
Systematic screening of protein-coding gene expression identified
HMMR as a potential independent indicator of unfavorable survival
in patients with papillary muscle-invasive bladder cancer. Biomed
Pharmacother. 120:1094332019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Man Y, Cao J, Jin S, Xu G, Pan B, Shang L,
Che D, Yu Q and Yu Y: Newly identified biomarkers for detecting
circulating tumor cells in lung adenocarcinoma. Tohoku J Exp Med.
234:29–40. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li W, Pan T, Jiang W and Zhao H:
HCG18/miR-34a-5p/HMMR axis accelerates the progression of lung
adenocarcinoma. Biomed Pharmacother. 129:1102172020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang X, Xia S, Li H, Wang X, Li C, Chao Y,
Zhang L and Han C: The deubiquitinase USP10 regulates KLF4
stability and suppresses lung tumorigenesis. Cell Death Differ.
27:1747–1764. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Roberts MS, Anstine LJ, Finke VS, Bryson
BL, Webb BM, Weber-Bonk KL, Seachrist DD, Majmudar PR and Keri RA:
KLF4 defines the efficacy of the epidermal growth factor receptor
inhibitor, erlotinib, in triple-negative breast cancer cells by
repressing the EGFR gene. Breast Cancer Res. 22:662020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kawabata KC, Ehata S, Komuro A, Takeuchi K
and Miyazono K: TGF-β-induced apoptosis of B-cell lymphoma ramos
cells through reduction of MS4A1/CD20. Oncogene. 32:2096–2106.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kubota T, Sasaki Y, Shiozawa E, Takimoto
M, Hishima T and Chong JM: Age and CD20 expression are significant
prognostic factors in human herpes virus-8-negative effusion-based
lymphoma. Am J Surg Pathol. 42:1607–1616. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ito H, Tsunoda T, Riku M, Inaguma S, Inoko
A, Murakami H, Ikeda H, Matsuda M and Kasai K: Indispensable role
of STIL in the regulation of cancer cell motility through the
lamellipodial accumulation of ARHGEF7-PAK1 complex. Oncogene.
39:1931–1943. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang J, Zhang Y, Dou Z, Jiang H, Wang Y,
Gao X and Xin X: Knockdown of STIL suppresses the progression of
gastric cancer by down-regulating the IGF-1/PI3K/AKT pathway. J
Cell Mol Med. 23:5566–5575. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Patwardhan D, Mani S, Passemard S,
Gressens P and El Ghouzzi V: STIL balancing primary microcephaly
and cancer. Cell Death Dis. 9:652018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
von Ehr A, Attaai A, Neidert N, Potru PS,
Ruß T, Zöller T and Spittau B: Inhibition of microglial TGFβ
signaling increases expression of Mrc1. Front Cell Neurosci.
14:662020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu Q, Bai W, Huang F, Tang J and Lin X:
Downregulation of microRNA-196a inhibits stem cell self-renewal
ability and stemness in non-small-cell lung cancer through
upregulating GPX3 expression. Int J Biochem Cell Biol.
115:1055712019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Worley BL, Kim YS, Mardini J, Zaman R,
Leon KE, Vallur PG, Nduwumwami A, Warrick JI, Timmins PF, Kesterson
JP, et al: GPx3 supports ovarian cancer progression by manipulating
the extracellular redox environment. Redox Biol. 25:1010512019.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sun Y, Hou L, Yang Y, Xie H, Yang Y, Li Z,
Zhao H, Gao W and Su B: Two-gene signature improves the
discriminatory power of IASLC/ATS/ERS classification to predict the
survival of patients with early-stage lung adenocarcinoma. Onco
Targets Ther. 9:4583–4591. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Borlado LR and Méndez J: CDC6: From DNA
replication to cell cycle checkpoints and oncogenesis.
Carcinogenesis. 29:237–243. 2008. View Article : Google Scholar : PubMed/NCBI
|
